H. Pieniaszek

发表

Relative Systemic Availability of Sulfapyridine from Commercial Enteric‐Coated and Uncoated Sulfasalazine Tablets

H. Pieniaszek, D. E. Resetarits, W. W. Wilferth, 1979, Journal of clinical pharmacology.

Safety, Tolerability, Pharmacokinetics, and Time Course of Pharmacologic Response of the Active Metabolite of Roxifiban, XV459, a Glycoprotein IIb/IIIa Antagonist, following Oral Administration in Healthy Volunteers

W. Ebling, H. Pieniaszek, S. Sy, 2002, Journal of clinical pharmacology.

Assessment of beta blockade with propranolol

D. Perrier, H. Pieniaszek, M. Mayersohn, 1981, Clinical pharmacology and therapeutics.

Variability in the Pharmacokinetics and Pharmacodynamics of Low Dose Aspirin in Healthy Male Volunteers

H. Pieniaszek, D. Kornhauser, I. Benedek, 1995, Journal of clinical pharmacology.

Disposition of moracizine (ethmozine) in healthy subjects after oral administration of radiolabelled drug

H. Pieniaszek, L. Dittert, R. Fogoros, 2006, European Journal of Clinical Pharmacology.

Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events

H. Pieniaszek, S. Kuhle, V. Marzinotto, 2005, Thrombosis and Haemostasis.

Determination of unlabeled and 13C6-labeled moricizine in human plasma using thermospray liquid chromatography-mass spectrometry.

H. Pieniaszek, C. C. Whitney, L. Shalaby, 1989, Journal of chromatography.

The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease

I. Gussak, B. Williams, W. Ebling, 2003, American journal of cardiovascular drugs : drugs, devices, and other interventions.

A double antibody radioimmunoassay for the determination of XV459, the active hydrolysis metabolite of roxifiban, in human plasma.

H. Pieniaszek, R. Olson, Y. Barrett, 2003, Journal of pharmaceutical and biomedical analysis.

Assessment of the Potential Pharmacokinetic Interaction Between Digoxin and Ethmozine

H. Pieniaszek, F. Marcus, R. Macfarland, 1985, Journal of clinical pharmacology.

Population pharmacokinetic meta-analysis with efavirenz.

J. Barrett, H. Pieniaszek, T. Ludden, 2002, International journal of clinical pharmacology and therapeutics.

Cholestyramine-induced inhibition of salicylazosulfapyridine (sulfasalazine) metabolism by rat intestinal microflora.

H. Pieniaszek, T. R. Bates, 1976, The Journal of pharmacology and experimental therapeutics.

Human moricizine metabolism. I. Isolation and identification of metabolites in human urine.

H. Pieniaszek, L. E. Richards, S. Shatzmiller, 1997, Xenobiotica; the fate of foreign compounds in biological systems.

Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia.

R. Wynn, T. Hua, W. Ebling, 2003, Blood.

Effect of Moricizine on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers

H. Pieniaszek, W. Schary, I. Benedek, 1992, Journal of clinical pharmacology.

antagonist Roxifiban: implications for the etiology of thrombocytopenia of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa Prospective testing for drug-dependent antibodies reduces the incidence

R. Wynn, W. Ebling, H. Pieniaszek, 2013 .

Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations.

H. Pieniaszek, A. Mutlib, S. Unger, 2003, Journal of pharmaceutical and biomedical analysis.

Disposition and exposure of the fibrinogen receptor antagonist XV459 on αIIBβ3 binding sites in the guinea pig

S. Mousa, W. Ebling, J. Barrett, 1999 .

Moricizine Pharmacokinetics in Renal Insufficiency: Reevaluation of Elimination Half‐Life

H. Pieniaszek, U. Michael, M. Mayersohn, 1992, Journal of clinical pharmacology.

A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion.

L. Grochow, R. Donehower, H. Pieniaszek, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-Dependent Pharmacokinetics of Warfarin in Healthy Volunteers

H. Pieniaszek, I. Benedek, S. P. King, 1995, Pharmaceutical Research.

Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.

T. Hua, J. Barrett, H. Pieniaszek, 2001, Thrombosis research.

Pharmacokinetic comparison of orally‐disintegrating metoclopramide with conventional metoclopramide tablet formulation in healthy volunteers

H. Pieniaszek, R. Fass, J. Thompson, 2009, Alimentary pharmacology & therapeutics.

Oxymorphone Extended Release Does Not Affect CYP2C9 or CYP3A4 Metabolic Pathways

H. Pieniaszek, A. Gammaitoni, H. Ahdieh, 2005, Journal of clinical pharmacology.

Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulfasalazine, in rats.

H. Pieniaszek, T. R. Bates, Henry J. Pieniaszek, 1979, Journal of pharmaceutical sciences.

Safety, Efficacy, and Pharmacokinetics of Balsalazide in Pediatric Patients With Mild-to-Moderate Active Ulcerative Colitis: Results of a Randomized, Double-blind Study

H. Pieniaszek, T. Attard, M. Heyman, 2009, Journal of pediatric gastroenterology and nutrition.

High-performance liquid chromatographic assay of sulfapyridine and acetylsulfapyridine in biological fluids.

W. Jusko, H. Pieniaszek, T. R. Bates, 1978, Journal of pharmaceutical sciences.

Single‐Dose Pharmacokinetics, Safety, and Tolerance of Linopirdine (DuP 996) in Healthy Young Adults and Elderly Volunteers

H. Pieniaszek, W. Fiske, R. Martz, 1995, Journal of clinical pharmacology.

Determination of bisnafide, a novel bis-naphthalimide anticancer agent, in human plasma by high-performance liquid chromatography with UV detection.

H. Pieniaszek, B. Brogdon, C. Lai, 1998, Journal of Pharmaceutical and Biomedical Analysis.

Enzyme Induction by Moricizine: Time Course and Extent in Healthy Subjects

H. Pieniaszek, I. Benedek, A. Davidson, 1994, Journal of clinical pharmacology.

Human moricizine metabolism. II. Quantification and pharmacokinetics of plasma and urinary metabolites.

H. Pieniaszek, M. Mayersohn, C. A. Robinson, 1999, Xenobiotica; the fate of foreign compounds in biological systems.

Pharmacokinetic Interactions of Moricizine and Diltiazem in Healthy Volunteers

H. Pieniaszek, W. Flamenbaum, I. Benedek, 1996, Journal of clinical pharmacology.

Elimination pathways of [14C]losoxantrone in four cancer patients.

M. Ratain, E. Vokes, H. Pieniaszek, 2001, Drug metabolism and disposition: the biological fate of chemicals.

Protein binding of brequinar in the plasma of healthy donors and cancer patients and analysis of the relationship between protein binding and pharmacokinetics in cancer patients

J. Bertino, H. Pieniaszek, Cecilia L Chi, 2004, Cancer Chemotherapy and Pharmacology.

Beta adrenergic blockade with propranolol in conscious euthyroid and thyrotoxic calves: dosage requirements and effects on heart rate and left ventricular performance.

D. Perrier, H. Pieniaszek, S. Goldman, 1981, Journal of Pharmacology and Experimental Therapeutics.

Gastrointestinal absorption of griseofulvin from corn oil-in-water emulsions: effect of amount of corn oil ingested in man.

T R Bates, H. Pieniaszek, T. R. Bates, 1977, Archives of dermatology.

Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist.

W. Ebling, H. Pieniaszek, D. Seiffert, 2007, Journal of pharmaceutical and biomedical analysis.

Integrated Pharmacokinetic/Pharmacodynamic Model of XV459, a Potent and Specific GPIIb/IIIa Inhibitor, in Healthy Male Volunteers

W. Ebling, J. Barrett, H. Pieniaszek, 2002, Journal of clinical pharmacology.

Moricizine Bioavailability via Simultaneous, Dual, Stable Isotope Administration: Bioequivalence Implications

J. Barrett, H. Pieniaszek, M. Mayersohn, 1999, Journal of clinical pharmacology.

Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces.

H. Pieniaszek, BatesTR, 1975, Research communications in chemical pathology and pharmacology.

Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine

H. Pieniaszek, H. Blumenthal, T. R. Bates, 1977, Clinical pharmacology and therapeutics.

Determination of DuP 128, an ACAT inhibitor and its sulphoxide and sulphone metabolites in human plasma by liquid chromatography.

H. Pieniaszek, B. Brogdon, C. Lai, 1994, Journal of pharmaceutical and biomedical analysis.

Determination of naltrexone and its major metabolite, 6-beta-naltrexol, in human plasma using liquid chromatography with electrochemical detection.

H. Pieniaszek, T. Emm, A. Davidson, 1996, Journal of pharmaceutical and biomedical analysis.